IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Success Rate, Continence, and Quality of Life With a Bioprosthetic Plug for Treating Complex Anal Fistula
This study has been completed.
Sponsor:
University Hospital, Basel, Switzerland
Collaborators:
St. Michael's Hospital, Toronto
Women's College Hospital
St. Claraspital AG
Mount Sinai Hospital, Canada
Information provided by (Responsible Party):
Michel Adamina, MD, PD, MSc, University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT01612195
First received: June 2, 2012
Last updated: May 16, 2013
Last verified: May 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Anal abscess-fistula disease is of common occurrence and has a significant impact on the quality of life of affected individuals. The course of abscess-fistula disease as well as its treatment modalities may affect anal continence. The present cohort study investigates the results of anal fistula plug surgery. In particular, this study focus on the impact of anal fistula plug surgery on fistula healing, quality of life, and anal continence. Fifty patients will be included and followed up at 6 weeks and 6 months after surgery in the clinic of participating surgeons.
| Condition | Intervention | Phase |
|---|---|---|
| Complex Anal Fistula | Procedure: Anal fistula plug | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Success Rate, Continence, and Quality of Life With a Bioprosthetic Plug for Treating Complex Anal Fistula |
Resource links provided by NLM:
Further study details as provided by Michel Adamina, MD, PD, MSc, University Hospital, Basel, Switzerland:
Primary Outcome Measures:
- Fistula healing [ Time Frame: 6 months ]Clinical healing of a complex anal fistula as assessed in the clinic at 6 weeks and 6 months after anal fistula plug surgery. Further assessment prn.
- Anal continence [ Time Frame: 6 months ]Evaluation of anal continence by means of a validated questionnaire, namely the Fecal Incontinence Severity Index, at 6 weeks and 6 months after anal fistula plug surgery.
- Quality of life [ Time Frame: 6 months ]Evaluation of health-related quality of life by means of a validated questionnaire, namely the Short-Form 36 version 2, at 6 weeks and 6 months after anal fistula plug surgery.
| Enrollment: | 46 |
| Study Start Date: | January 2007 |
| Study Completion Date: | January 2012 |
| Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Anal fistula plug |
Procedure: Anal fistula plug
All patients have a draining seton for at least 6 weeks prior placement of the anal fistula plug. All patients are administered a general anesthetic and are operated in the lithotomy position. The seton is removed, but no curettage or irrigation of the fistula tract is performed. The plug is inserted through the internal opening, and pulled through the external opening until it fit snugly and its base is sutured to the internal sphincter with 2 interrupted 2-0 polyglactin 910 sutures. The tip of the plug is cut at skin level and not sutured. The external opening is left open to allow for drainage. The patient is instructed to restrict physical and sexual activity for 2 weeks postoperatively. Patients are seen in the post-operative clinic at 10 days, 6 weeks and 6 months as per protocol.
Other Name: Anal fistula plug Surgisis®
|
Detailed Description:
Anal abscess-fistula disease is of common occurrence and has a significant impact on the quality of life of affected individuals. The clinical course of abscess-fistula disease as well as its treatment modalities may affect anal continence. Anal fistula plug surgery is an Health Canada and FDA approved surgical treatment that has demonstrated promising results in terms of fistula healing and minimal patients' burden. The present cohort study prospectively investigates the results of anal fistula plug surgery performed in teaching hospitals affiliated to the University of Toronto. In particular, this study focus on the impact of anal fistula plug surgery on health-related quality of life, and its 2 major determinants anal continence and fistula healing. Fifty patients will be included and followed up at 6 weeks and 6 months after surgery in the clinic of participating surgeons. Quality of life and anal continence will be measured with the validated Short Form-36 Health Survey (SF-36 v2) and Fecal Incontinence Score Index (FISI) questionnaires, respectively. It is expected that the present study will provide objective information on the results and generalizability of anal fistula surgery, as well as on its impact on health-related quality of life and anal continence.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Complex anal fistula as defined by
- high transsphincteric fistula
- extrasphincteric fistula
- suprasphincteric fistula
- recurrent fistula
- multiple fistula openings, including horseshoe fistula
- imperfect continence- jeopardized anal continence (anterior transsphincteric fistula, prior anal surgery)
Exclusion Criteria:
- Uncomplicated fistula curable by simple fistulotomy
- History of inflammatory bowel disease
- Chronic immunosuppressive treatment (ie, systemic steroids for >3 days)
- Clinical heart failure as defined by a CCS angina severity class ≥ III
- Untreated cancer or cancer diagnosed/treated (all modalities) within 6 months
- Estimated life expectancy inferior to 6 months
- Incompetent subject
- Pregnancy
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01612195
Please refer to this study by its ClinicalTrials.gov identifier: NCT01612195
Locations
| Switzerland | |
| University of Basel & Kantonsspital St.Gallen | |
| Basel & St.Gallen, Switzerland, 4031 & 9007 | |
Sponsors and Collaborators
University Hospital, Basel, Switzerland
St. Michael's Hospital, Toronto
Women's College Hospital
St. Claraspital AG
Mount Sinai Hospital, Canada
Investigators
| Principal Investigator: | Michel Adamina, MD, PD, MSc | University of Basel |
More Information
| Responsible Party: | Michel Adamina, MD, PD, MSc, Senior Scientist, University Hospital, Basel, Switzerland |
| ClinicalTrials.gov Identifier: | NCT01612195 History of Changes |
| Other Study ID Numbers: |
AFP-2 |
| Study First Received: | June 2, 2012 |
| Last Updated: | May 16, 2013 |
Keywords provided by Michel Adamina, MD, PD, MSc, University Hospital, Basel, Switzerland:
|
anal fistula anal continence health-related quality of life |
Additional relevant MeSH terms:
|
Fistula Rectal Fistula Pathological Conditions, Anatomical Intestinal Fistula Digestive System Fistula |
Digestive System Diseases Intestinal Diseases Gastrointestinal Diseases Rectal Diseases |
ClinicalTrials.gov processed this record on June 23, 2017